Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Drag sustained release stent

A drug and slow-release technology, applied in stents, medical science, coatings, etc., can solve the problems of time asynchronous matching that affect patients' breathing, stent displacement, and mucosal outcome

Pending Publication Date: 2019-03-01
乐畅医疗器械(上海)有限公司
View PDF0 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Among them, the non-degradable stent has a relatively strong supporting force, but it needs a second operation to remove it about 15-30 days after implantation, causing secondary injury to the patient; the degradable stent is usually made of polylactic acid materials with low strength and elastic modulus. Like balloon dilatation, it is not enough to open nasal passages blocked by pathological tissues such as nasal polyps and cysts alone, so it is usually used as an adjunct to FESS surgery. The US FDA has approved the Propel stent from Intersect ENT for the treatment of chronic sinusitis , the stent has a certain supporting capacity and is coated with drug sustained-release preparations. The drug on the stent is basically released within the first two weeks after implantation in the nasal cavity, which is the same as the time for wound healing and mucosal outcome after FESS surgery in clinical practice. out of sync match
And we know that FESS surgery will remove a considerable part of the nasal cavity, resulting in a large area of ​​continuous wounds, resulting in postoperative nasal bleeding
Clinically, filling hemostatic sponge and cotton gauze is usually used to stop bleeding on the wound surface, but on the one hand, the filler blocks the already narrow nasal passage, which affects the patient's breathing; Implantation site does its job

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drag sustained release stent
  • Drag sustained release stent
  • Drag sustained release stent

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0074] Such as Figure 2-Figure 3 As shown, a stent graft 100 includes a stent 102 and a polymer film 101, and the stent 102 and the polymer film 101 are connected together to form a stent graft. The polymer film is a degradable polymer film.

[0075] The stent 102 of the present invention consists of a single degradable fiber thread that is twisted and wound on a weaving mold to form a network-like hollow structure. The ester ratio is 10:90 or 15:85, and the intrinsic viscosity is 1.0-1.6dl / g). The stent body composed of the degradable stent wire will be completely degraded within 30-90 days after being implanted in the nasal cavity.

[0076] The upper and lower edges of the bracket include 15 corolla 104 (apex), and the silk threads are interlaced and superimposed together to form intersections 103. An intersection point 1031 is located above the reversely wound silk thread, and then the next immediately adjacent intersection point 1032 is located below the reversely wound...

Embodiment 2

[0082] A stent graft 100, similar to Embodiment 1, the difference is that the polymer film 101 used in this embodiment is a straight cylindrical non-degradable polymer film made of polyvinyl chloride, or polyurethane, polyamide and other materials , the thickness of the film is about 0.1-0.5mm, and its diameter is the same as figure 1 The illustrated stents 102 have comparable inner diameters. Such as Figure 6 As shown, there is a traction line 106 formed by crossing non-degradable sutures (polypropylene or nylon, etc.) in the middle of the polymer film, and the traction line 106 can be clamped by the tool and pulled out of the nasal cavity to bring the polymer film out of the nasal cavity .

[0083] Such as figure 1 As shown, the polymer film 101 and the stent 102 are sutured together at the corolla 104 to form a covered stent 100 through a degradable suture (such as Jiaxiu pure natural collagen suture from Hunan Ranyuan Company), and the polymer film 101 is sutured on O...

Embodiment 3

[0085] This embodiment is a drug sustained-release stent loaded with a drug coating, which may include the stent graft 100 shown in Embodiment 1 or Embodiment 2. The stent graft 100 includes a stent 102 and a polymer film 101, a stent 102 and a polymer membrane. The material membranes 101 are connected together to form a stent graft. Both the stent 102 and the polymer film are provided with a layer of drug coating, and the drug coating on the stent 102 and the polymer film 101 is composed of controlled-release polymers and drugs such as anti-inflammatory drugs, antibacterial drugs, anticancer drugs or hemostatic drugs. mixed.

[0086] Specifically, the stent graft 100 of this embodiment is the second stent graft 100 (degradable polymer film) in the first embodiment, and the drug coating on the polymer film 101 is released faster than the drug coating on the stent 102. . The drug coating on the polymer film 101 may have multiple variations, for example, the same drug as that ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

The invention provides a drag sustained release stent. The drag sustained release stent is characterized by comprising a stent body and a polymer membrane, and the stent body and the polymer membraneare connected together; the polymer membrane is a biodegradable polymer membrane or a non-biodegradable polymer membrane, the polymer membrane and / or the stent body is provided with at least one layerof drug coating, and the drug coating includes one or several kinds of antibacterial drugs, anti-inflammatory drugs, anti-cancer drugs and hemostatic drugs. The drug sustained release stent is applied to the treatment of sinusitis, and can not only play a supporting and continuously dosing role in a lesion location after FESS surgery, but also play a role in hemostasis after the surgery.

Description

technical field [0001] The invention relates to a drug slow-release bracket. Background technique [0002] Rhinosinusitis is a common inflammatory disease that occurs in the sinus mucosa. It is caused by internal and external pathogenic factors (allergies, bacteria, viruses, fungi, etc.) and genetic and anatomical factors. Its immune mechanism is complex. According to the course of the disease, it can be divided into acute rhinosinusitis of less than 12 weeks and chronic rhinosinusitis of more than 12 weeks. Rhinosinusitis is often associated with allergic rhinitis, non-allergic rhinitis, asthma and other upper and lower respiratory diseases, seriously affecting the quality of life of patients. Studies have shown that patients with chronic sinusitis experience more severe physical pain and poorer social interaction than those with chronic obstructive pulmonary disease and congestive heart failure. [0003] The etiology of chronic sinusitis is not completely clear, it may b...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61F2/90A61L31/10A61L31/16
CPCA61L31/10A61L31/16A61F2/90A61F2210/00A61L2300/45C08L67/04
Inventor 余洪猛李天明杨海
Owner 乐畅医疗器械(上海)有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products